Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data (Q31143314)

29 June 2017

title

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data (English)

1 reference

29 June 2017

J A Cohen

1

1 reference

29 June 2017

P A Calabresi

2

1 reference

29 June 2017

S Chakraborty

3

1 reference

29 June 2017

K R Edwards

4

1 reference

29 June 2017

T Eickenhorst

5

1 reference

29 June 2017

W L Felton

6

1 reference

29 June 2017

E Fisher

7

1 reference

29 June 2017

R J Fox

8

1 reference

29 June 2017

A D Goodman

9

1 reference

29 June 2017

C Hara-Cleaver

10

1 reference

29 June 2017

G J Hutton

11

1 reference

29 June 2017

P B Imrey

12

1 reference

29 June 2017

D M Ivancic

13

1 reference

29 June 2017

B F Mandell

14

1 reference

29 June 2017

J E Perryman

15

1 reference

29 June 2017

T F Scott

16

1 reference

29 June 2017

T T Skaramagas

17

1 reference

29 June 2017

H Zhang

18

1 reference

29 June 2017

ACT Investigators

19

1 reference

29 June 2017

publication date

21 January 2008

1 reference

Multiple Sclerosis Journal

29 June 2017

published in

1 reference

29 June 2017

volume

14

1 reference

29 June 2017

issue

3

1 reference

29 June 2017

page(s)

370-382

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

29 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A method for registration of 3-D shapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Intrarater and interrater reliability of the MS functional composite outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458507083189

21 January 2018

Identifiers

DOI

10.1177/1352458507083189

1 reference

29 June 2017

1 reference